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INTRODUCTION
The in vivo hydrolysis of GM2 ganglioside (GM2) requires the correct 
synthesis, folding and interaction of three gene products. Mutations 
in any of these genes can result in one of the three forms of the lyso-
somal storage disease, GM2 gangliosidosis. The HEXA and HEXB genes 
encode the ~60 kDa α- and β- subunits, respectively, of the heterodi-
meric β-hexosaminidase A (HexA) isozyme. Deficiencies in either the 
α- or β-subunit leads to Tay-Sachs (TSD) or Sandhoff disease (SD), 
respectively. These are autosomal recessive, progressive neurode-
generative disorders that account for the vast majority of GM2 gan-
gliosidosis patients. However, it has been estimated that only ~10% 
of normal HexA activity is all that is needed to prevent GM2 storage.1
The HEXA and HEXB genes are evolutionarily related, with their pro-
tein products sharing ~60% sequence identity. While each subunit 
contains its own active site, residues from the neighboring subunit 
must stabilize the site in order for it to become functional.2–4 Thus, 
monomers are not active. In normal human cells, there are two major 
Hex isozymes, HexA (αβ) and HexB (ββ). An unstable isozyme is also 
detectable at very low levels in SD patient samples, HexS (αα). Due 
to sequence variations in each of the α- and β-subunit-subunit inter-
faces, the stability of the active dimeric forms of the isozymes vary 
markedly, i.e., the stability of HexB> HexA>> HexS. While all three 
isozymes can hydrolyze soluble, neutral substrates, e.g., 4-methylum-
belliferyl 2-acetamido-2-deoxy-β-D-glucopyranoside (MUG), only the 
α-subunit-containing HexA and HexS isozymes can efficiently hydro-
lyze negatively charged substrates,5 such as  MUG-6-sulfate6 (MUGS). 
The variation in substrate specificities is due to a positively charged 
binding pocket in the α-subunit, which is negatively charged in the 
β-subunit.2,3,7 This pocket is also responsible for binding the nega-
tively charged sialic acid moiety in GM2.2,8
The third gene responsible for GM2 gangliosidosis, GM2A, 
encodes the GM2 activator protein (GM2AP).9 Mutations in the 
GM2A gene lead to the ultra-rare AB-variant form. GM2AP is a small, 
glycolipid-transport protein that removes a molecule of GM2 from 
the lysosomal membrane and presents it to HexA for hydrolysis 
(reviewed in refs. 10,11). Thus, HexA and the GM2AP-GM2 complex 
must interact in the lysosome to form a soluble, active quaternary 
complex with the GM2 substrate correctly positioned for hydrolysis 
by the active site of the α-subunit. This complex has been modeled.2 
Consistent with the genetic and biochemical evidences that only 
HexA can efficiently turnover GM2, nonconserved protein patches, 
located in different areas of the α- and β-subunits, were predicted 
by the model (Figures 1 and 2) to be required for efficient interac-
tion of the GM2AP-GM2 complex with HexA.2
Received 16 December 2015; accepted 17 December 2015
2329-0501
15057








Official journal of the American Society of Gene & Cell Therapy
Engineering a protein to hydrolyze GM2 ganglioside
MB Tropak et al.
Tay-Sachs or Sandhoff disease result from mutations in either the evolutionarily related HEXA or HEXB genes encoding respectively, 
the α- or β-subunits of β-hexosaminidase A (HexA). Of the three Hex isozymes, only HexA can interact with its cofactor, the GM2 
activator protein (GM2AP), and hydrolyze GM2 ganglioside. A major impediment to establishing gene or enzyme replacement 
therapy based on HexA is the need to synthesize both subunits. Thus, we combined the critical features of both α- and β-subunits 
into a single hybrid µ-subunit that contains the α-subunit active site, the stable β-subunit interface and unique areas in each 
subunit needed to interact with GM2AP. To facilitate intracellular analysis and the purification of the µ-homodimer (HexM), CRISPR-
based genome editing was used to disrupt the HEXA and HEXB genes in a Human Embryonic Kidney 293 cell line stably expressing 
the µ-subunit. In association with GM2AP, HexM was shown to hydrolyze a fluorescent GM2 ganglioside derivative both in cellulo 
and in vitro. Gene transfer studies in both Tay-Sachs and Sandhoff mouse models demonstrated that HexM expression reduced 
brain GM2 ganglioside levels.
Molecular Therapy — Methods & Clinical Development (2016) 3, 15057; doi:10.1038/mtm.2015.57; published online 2 March 2016
1Genetics and Genome Biology, SickKids, Toronto, Ontario, Canada; 2Department of Ophthalmology and Gene Therapy Center, University of North Carolina, Chapel Hill, North 
Carolina, USA; 3Medical Genetics/Department of Pediatrics, Queen’s University, Kingston, Ontario, Canada; 4Department of Chemistry and Biology, Ryerson University, Toronto, 
Ontario, Canada; 5Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; 6Department of Laboratory Medicine and Pathology, University of Toronto, 
Toronto, Ontario, Canada. Correspondence: BL Mark (brian_mark@umanitoba.ca) Or D Mahuran (hex@sickkids.ca)
Construction of a hybrid β-hexosaminidase subunit 
capable of forming stable homodimers that hydrolyze 
GM2 ganglioside in vivo
Michael B Tropak1, Sayuri Yonekawa1, Subha Karumuthil-Melethil2, Patrick Thompson3, Warren Wakarchuk4, Steven J Gray2,  
Jagdeep S Walia3, Brian L Mark5 and Don Mahuran1,6
ARTICle
2
Engineering a protein to hydrolyze GM2 ganglioside
MB Tropak et al.
Molecular Therapy — Methods & Clinical Development (2016) 15057 Official journal of the American Society of Gene & Cell Therapy
The heterodimeric nature of HexA is a major impediment to devel-
oping either gene therapy or enzyme replacement therapy (ERT) for 
TSD and SD. Previous gene therapy approaches for  Tay-Sachs and 
Sandhoff have relied on delivery of a single Hex subunit, or a dual 
vector approach separately delivering both subunits.12–17 While these 
studies have generated promising results, they are not ideal. Our 
approach to overcoming this impediment, is to engineer a new artifi-
cial Hex subunit (µ) that contains the α-active site, regions on the sur-
faces of the α- and β-subunits that are needed to functionally interact 
with the GM2AP-GM2 complex in vivo, and the β-subunit interface 
needed to form a new stable µ-homodimer (HexM). The resulting 
size of the DNA-coding sequence for µ is well within the packaging 
capacity of the efficient self-complementary (sc)AAV.18 There have 
also been reports that intravenously administered AAV9 can cross 
the blood–brain barrier, wherein the efficiency of gene transfer to the 
CNS was greatly enhanced by the use of scAAV vectors.19–21
ReSUlTS
Constructing HexM
We previously demonstrated that neither of two hybrid Hex subunit 
engineered by ourselves22 or others23 were able to hydrolyze GM2 
in a GM2AP-dependent manner as homodimers.22 Both of these 
subunits were constructed by substituting regions of α-subunit 
sequence in the β-subunit, e.g., HexBMM.22 Thus, we engineered a 
new hybrid based on the human α-subunit. To promote rapid dimer-
ization and stability, the dimerization interface of the α-subunit 
was exchanged with that of the β-subunit. Next, two small areas 
in the C-terminal 20% of the β-subunit, predicted to be necessary 
for GM2AP binding, were used to replace the aligned sequences in 
the α-subunit (Figures 1 and 2 and Supplementary Table S1). In the 
process of making this new construct, the nucleotide sequence was 
also codon-optimized for more efficient protein expression in mam-
malian cells (Supplementary Figure S1).
Establishing stably transfected HEXA-/-/HEXB-/- HEK-293 cells 
secreting HexM-His6
One of the problems we encountered in our previous attempt to 
engineer a β-subunit-based Hex hybrid subunit was the formation of 
heterodimers between our transfected hybrid and the endogenous 
Figure 1  Model of the active HexM quaternary complex. The μ-subunit 
of HexM is derived from the α-subunit (orange) of human HexA, which 
was modified to include the stable homodimer interface (magenta) 
formed between the β-subunits (teal) of human HexB and a region 
from the β-subunit predicted to interact with GM2AP. The GM2AP (grey) 
bound to GM2 (spheres) was modeled onto HexA as described2,3 and this 

















Figure 2 Substitutions that were made from the Hex β-subunit sequence into the human α-subunit to produce the μ-subunit of homodimeric HexM. 
Changes in; rectangles = β-like dimer interface; those in ovals = β-like GM2AP binding; and the one in a hexagon = both β-like interface and activator 
binding sites.
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normal α subunit in SD cells. These α-hybrid heterodimers were then 
capable of hydrolyzing a fluorescent GM2 derivative (NBD-GM2) in 
cellulo and produced false positive results.22 To address this prob-
lem, we used CRISPR-based genome editing24 to render both the 
HEXA and HEXB genes in clonal populations of HEK cells nonfunc-
tional (HEKHexABKO). The double inactivation of HEXA/B genes 
was confirmed by: (i) direct sequencing or PCR analyses of exon1 
and 11 of HEXA and exon 1 of HEXB (Supplementary Figure S2a), 
which were targeted by the guide RNAs we used; (ii) western blot 
analyses of the wild type (WT) versus the HEKHexABKO cell lysates 
(Supplementary Figure S2b); and (iii) Hex activity assays based on the 
fluorogenic substrates MUG and MUGS (Supplementary Figure S2c). 
These results confirmed the presence of deletions in both alleles of 
HEXA and HEXB (Supplementary Figure S2a) resulting in a reduction 
of 3 log orders in total MUGS and MUG activities. The very low levels 
of residual activity likely result from other neutral glycosidases, such 
as O-GlcNAcase.25
The HEK-HexABKO cells were next transfected with a construct 
encoding the µ-subunit with a C-terminal His6 tag. A clonal popu-
lation of these cells, stably expressing high levels of HexM-His6 
 (HEK-HexABKO-HexMHis) activity, was selected for further study. 
Initially, it was confirmed that these live cells could hydrolyze 
NBD-GM2, which we26 have previously shown to be taken-up by 
cultured cells and transported to the lysosome where it is primarily 
hydrolyzed by HexA in a GM2AP-dependent manner (Figure 3a,b). 
These in cellulo data were confirmed in vitro by comparing the 
activities of purified HexA and HexM-His6 toward NBD-GM2 in the 
presence or absence of recombinant human GM2AP (rGM2AP). Our 
previously constructed β-base hybrid (HexBMM), in its enriched 
homodimeric form,22 was used as a negative control. These assays 
were performed using an equal number of MUGS units of each 
isozyme (Figure  3c,d). Interestingly, the resulting data suggest 
that both active sites in HexM are able to bind and hydrolyze a 
GM2:GM2AP complex simultaneously, given that they can do this 
with the smaller MUGS substrate (Figure  4c,d; Table  1, discussed 
below). Based on the crystal structures of HexA, HexB, and GM2AP, a 
model was constructed to predict whether HexM could simultane-
ously bind a GM2:GM2AP complex at each of its two active sites. The 
resulting model suggests this could occur without significant steric 
hindrance (data not shown).
Characterization of HexM
We have previously shown that a C-terminal His6-tag does not affect 
the kinetics of the precursor form of HexB, which is indistinguish-
able from the kinetics of the mature lysosomal form.27 Furthermore, 
we have shown that the His6-tag is removed once the enzyme enters 
the protease-rich environment of the lysosome,27 where proteolytic 
processing produces the mature,  multi-polypeptide-containing 
subunits28 (reviewed in ref. 11). Thus, we purified the secreted pre-
cursor form of HexM-His6 using Ni-NTA resin (Figure 4a), and com-
pared its melting temperature (Tm) to those of purified placental 
HexA and HexB, as determined using differential scanning fluo-
rimetry29,30 (Figure 4b). The calculated Tm for HexB and HexM were 
virtually identical at 61 and 62 °C, respectively. In contrast, the Tm 
calculated for HexA was significantly lower at 53 °C. These data indi-
cate that the β-subunit interface was successfully transferred to the 
µ-subunits of HexM.
Using the purified His6-tagged precursor form of HexM and the 
purified mature form of placental HexA,31 the KM and Vmax values for 
each isozyme were determined for both the MUG (Figure 4c) and 
MUGS (Figure 4d) substrates and compared to previously published 
data for HexB and HexS (Table  1). The KM and Vmax of the α- and 
β-subunits’ active sites are known to differ for the MUG and MUGS 
substrates.6 As reported in Table  1, HexA, HexM, and HexS have 
virtually the same KM for MUGS. This result is expected, since the 
β-active site in HexA (and HexB) has a very low affinity for negatively 
charged substrates, and thus would not contribute significantly to 
the KM determination for HexA. However, the Vmax of MUGS for HexM 
is ~2-fold that for HexA (Fig.  4d). This was also expected, as both 
active sites in HexM should be able to hydrolyze negatively charged 
MUGS.
Interestingly, the Vmax of HexA for MUG is ~2-fold higher than that 
of HexM. MUG can be hydrolyzed by either the α- or β-active site; 
however the β-site has a significantly high affinity (lower KM) and 
turnover rate (Vmax) for this substrate than does the α-site.
6 Thus, the 
KM value of HexA for MUG is strongly influenced by its β-site while its 
Vmax value would be the average rate of hydrolysis for both subunits 
(Figure 4c). This is consistent with the observation that the Vmax of 
MUG for HexA, ~10 moles (MU) h−1 g−1 (Hex), is virtually equal to the 
average of those determined for HexB and HexM (Table 1).
Confirmation that HexM oligosaccharides contain M6P residues
Most soluble lysosomal enzymes, including Hex, depend on their 
Asn-linked oligosaccharides being specifically tagged in the ER/
Golgi with mannose-6-phosphate residues (M6P) to both target 
them to lysosomes and allow their secreted forms to be “recap-
tured” by other cells.32,33 This could be advantageous for develop-
ing effective gene therapy. Although evidence that the recapture 
system in brain requires M6P-liganded enzyme is sparse, Kyttälä 
Figure 3 HexM is capable of hydrolyzing NBD-GM2 in a  GM2AP-
dependent manner. In cellulo hydrolysis of NBD-GM2 was accessed by 
HPTLC separation of the Folch-extracted NBD-glycolipids from HexM 
expressing (+HexM) and untransfected (-HexM) HEKHexABKO cells. The 
upper phase (a) contains acidic glycolipids (gangliosides) and the lower 
phase (b) contains primarily neutral glycolipids. Conduritol B epoxide (50 
µmol/l), a nonreversible inhibitor of glucocerebrosidase, was also present 
in the medium to inhibit NBD-GlcCer degradation.26 (c) In vitro assay of 
NBD-GM2 hydrolysis by equal MUGS units of three human Hex isozymes; 
HexBMM,22 HexA and HexM; in the absence (−) or presence (+) of human 
rGM2AP. (d) Quantitative comparison of hydrolysis of NBD-GM2 to  NBD-
GM3 by HexA and HexM (n = 2) expressed in arbitrary units (AU) and as 
a ratio of band intensities corresponding to NBD-GM3 and NBD-GM2 in 
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et  al.34 have reported that by adding 5 mmol/l M6P along with 
recombinant aspartylglucosaminidase to the growth medium of 
 aspartylglucosaminidase-deficient mouse primary neurons, a sig-
nificant amount of the enzyme could be blocked from being endo-
cytosed after a 24 hours incubation period.
In order to confirm that HexM also contains M6P residues, 
the 48-hour growth medium (conditioned medium) from 
 HEK-HexABKO-HexMHis cells was collected and used to replace 
the medium in which an adult TSD patient fibroblast line35 was 
being grown. Lysates from these TSD cells, grown for 48 hours in 
conditioned medium produced a 40-fold increase in MUGS activ-
ity; whereas cells grown in conditioned medium containing M6P 
monosaccharides (5 mmol/l) produced only a 10-fold increase in 
specific activity (~75% reduction in endocytosis, Table 2).
Figure 4 Characterization of the heat stability and kinetic properties of HexM as compared to other Hex isozymes. (a) Protein stained SDS-PAGE gel 
demonstrating the purity of secreted HexM after Ni-NTA chromatography. The secreted, purified HexM precursor polypeptide (µp) versus the major 
mature α- and β- polypeptides (αm, βm) of isolated placental HexA. Molecular weight standards (Std) are shown at the right. (b) Confirmation was 
obtained using differential scanning fluorimetry that the β-subunit interface was successfully transferred into the HexM protein structure. The Tm of 
HexA calculated from its heat denaturation curve (solid line) was significantly lower (~10 °C) than those calculated for HexB (dotted line) and HexM 
(dashed line), which were virtually identical. (c,d) Comparison of the kinetics of purified HexM versus HexA for artificial substrates. The Km and Vmax values 
of HexM (open circles) and HexA (filled squares) for the MUG (c) and MUGS (d) substrates were determined from the specific activities of each isozyme 
(y-axis) at various concentrations of each substrate (x-axis) and fitted to the Michaelis-Menten equation using Prism Graphpad.
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Table 1 Comparison of Km and Vmax values of HexM toward a neutral and a negatively charged artificial substrate with those of other Hex isozymes
Hex MUG Km (mmol/l) MUG Vmax
a MUGS Km (mmol/l) MUGS Vmax
a Reference
M (μμ)b 1.10 ± 0.06 4.7 ± 0.1 0.21 ± 0.01 3.13 ± 0.03 PRc
A (αβ) 0.67 ± 0.06 9.7 ± 0.3 0.26 ± 0.02 1.32 ± 0.03 PR
S (αα) 1.5 ± 0.2 2.0 ± 0.1d 0.3 ± 0.1 0.94 ± 0.04d 7
B (ββ) 0.71 ± 0.1 14.5 ± 0.5 NDe NDe 7
aMoles (MU) h−1 g−1 (Hex). bIndicates a homodimer of our α-based hybrid subunit. cPresent report. dThese values may be low due to the presents of significant 
amounts of inactive HexS (an unstable isozyme). eNot determined because of insufficient activity toward MUGS (MUG/MUGS ~1/300).
5
Engineering a protein to hydrolyze GM2 ganglioside
MB Tropak et al.
Molecular Therapy — Methods & Clinical Development (2016) 15057Official journal of the American Society of Gene & Cell Therapy
Intracranial administration of vectors expressing HexM in TSD mice 
reduces the level of accumulated GM2 ganglioside
To determine the functionality of HexM in lowering the GM2 lev-
els in vivo, we performed intracranial injections of scAAV9 vectors 
containing either the HexM gene (HEXM), HEXA, or HEXBMM22 into 
the left hemisphere of 4-month-old Tay-Sachs hexa-/- mice. Two mice 
were injected with a mixture of one of the vectors and an  AAV9-GFP 
vector at a dose of 109 vector genomes (vg) of each vector. Two 
additional mice were injected with the AAV9-GFP vector alone. 
Coronal sections from the injected brain regions were subjected 
to immuno-histochemistry (IHC) against GFP and GM2 (Figure  5). 
Extensive expression of GFP throughout the lateral cortex and stria-
tum is apparent on the ipsilateral side, with scattered GFP-positive 
cells visible on the contralateral side (Figure 5a–d). This is consistent 
with axonal transport of AAV9 that has been reported.36 The Hex 
expression is expected to overlap with the areas of GFP expression, 
since identical AAV capsids, vector regulatory sequences, and doses 
were used for all vectors. GM2 accumulation is clearly visible at 5 
months of age in these mice. As expected, in the case of sections 
from mice injected with GFP vector alone, there is no decrease in 
the level of GM2 accumulation (Figure 5e) on the ipsilateral side of 
the brain compared to the contralateral side. In the case of brain 
sections from mice injected with a mix of GFP and different Hex vec-
tors, there is visible reduction in the GM2 levels on the injected side 
of the brain compared to the contralateral side of the same section 
(Figure 5f–h), and this reduction overlaps with the area of peak GFP 
expression (Figure  5b–d). To control for variability between mice, 
the comparison is mainly between the ipsilateral and contralateral 
sides of the same mouse. The extent of reduction in GM2 levels, 
apparent by the lighter DAB staining in these sections, is clear in the 
sections from all three HEX vector-treated mice. The HEXM vector 
(Figure  5h) was at least as efficient in reducing GM2 levels as the 
vector containing the HEXA gene (Figure 5g) and both of these were 
significantly more efficient than the vector containing the HEXBMM 
gene (Figure 5f ).
Reduced GM2 ganglioside accumulation in neonatal SD mice 
following the intravenous injection of a vector expressing HexM
Neonatal SD (hexb-/-) mice were injected intravenously with a 
scAAV9.47 vector containing a synthetic promoter to drive the 
expression of the HEXM gene. Eight-week postinjection the mice 
were sacrificed and GM2 levels (relative to those of GD1a) and 
enzyme activity toward MUGS and MUG (relative to total protein) 
from the mid-brain homogenate were determined. Although 
the Hex activity in the brains of the mice injected with the vector 
expressing the HexM µ-subunit was only slightly increased above 
those in mice injected with an empty vector, GM2 levels in these 
mice were significantly decreased (Figure 6, HexM versus vehicle). 
However, the GM2 levels in these mice were not reduced to the 
levels found in mice heterozygous for the hexb deletion mutation 
(Figure 6, HexM versus Het). This observation is likely due to a low 
level of gene transfer into the brain from the intravenous injec-
tion of the HEXM vector, which can also be inferred from the small 
increases in MUG and MUGS activity found in the same samples.
DISCUSSION
GM2 gangliosidosis (TSD and SD) presents challenges to develop-
ing both ERT and gene therapies in that the only Hex isozyme that 
turns over GM2 in vivo, HexA, is a heterodimer composed of simi-
lar but non-identical subunits. AAV are limited in their packaging 
capacity, i.e., ~4.5 kb for traditional single-strand AAV, and ~2.1 kb 
for the more efficient scAAV.18 The DNA coding sequences alone 
for both the α- and β-subunits of HexA total ~3.2 kb. Packaging 
only the deficient subunit is well within the size constraints of the 
AAV genome. However, overexpression of only one of the sub-
units would not lead to a similar level of expression and secretion 
of the missing heterodimeric HexA isozyme (to be recaptured by 
other non-infected cells), as the normal endogenous subunit would 
become a limiting factor. Much the same problem exists for ERT, 
which would require the mammalian cells producing the enzyme 
to be transfected with vectors encoding both subunits. Additionally, 
the secreted Hex from these cells would have to be purified and the 
Table 2 The effects of M6P on the internalization of HexM, 
secreted into the growth medium of transfected HEK (HEXA-/-, 
HEXB-/-) cells (conditioned medium), by adult TSD cells 








aFinal concentration in the adult TSD cells’ growth medium. bMUGS, nmoles 
hydrolyzed * h−1 * mg−1 (total lysate protein) ± standard deviation (n = 3). 
cNot determined.
Figure 5 Reduction in GM2 ganglioside levels following intracranial 
injection of AAV9-Hex vectors. Four-month-old Tay-Sachs disease knock out 
mice received a single unilateral intracranial injection (left side) of either 
AAV9-GFP (109 vg) or a 2-vector mixture containing equal amounts (109 vg 
each) of AAV9-GFP and an AAV9-Hex vector, as designated on the left panel. 
Coronal sections of the brain were analyzed by immunohistochemistry 
(IHC) for green fluorescent protein (GFP) expression to indicate vector 
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Hex isozymes separated. Our approach to overcoming these chal-
lenges was to design a hybrid Hex subunit comprised of the desired 
functional areas of both the α- and β-subunits that could form 
stable homodimers and, using the GM2AP as a co-factor, turnover 
GM2 in vivo. We22 and others23 have previously attempted to accom-
plish this by modifying the stable β-subunit with α-sequences. 
However our previously published data demonstrated that nei-
ther homodimeric forms of these β-based hybrids could efficiently 
hydrolyze GM2 in a human rGM2AP dependent manner in vitro,22 
e.g., HexBMM (Figure 3c).
The major problem in evaluating the ability of any homodimer 
of an engineered α-/β-hybrid subunit to hydrolyze GM2 in TSD/
SD patient cells or animal models is the potential for the hybrid to 
form an active heterodimer with the remaining endogenous WT 
subunit, thereby masking its inactivity as a homodimer.22 There are 
two additional problems in testing gene therapy or ERT in the com-
mon mouse models. The first is that mice have a biological bypass 
system not found in humans, that allows them to hydrolyze GM2 
through first converting it to its asialo derivative, GA2, which is then 
hydrolyze, although poorly, by mHexB37 in a mGM2AP-dependent 
manner.38 Thus the TSD mouse has only a mild, slowly progress-
ing phenotype. This suggests that a significant increase in HexB 
or possibly even HexS activity particularly in the SD mouse model 
could produce a decrease in the level of stored GM2 and increased 
lifespans. On the other hand, human patients lack the lysosomal 
sialidase necessary to convert GM2 to GA2 and their hGM2AP is 
much more specific for the HexA isozyme than is the mGM2AP.39 
This highlights another problem in evaluating ERT or gene transfer 
using  human-based enzyme or expressed cDNA in animal mod-
els; i.e., the vagaries of the strength and specificities of the three 
sets of interspecies protein–protein interactions required to form 
the active quaternary complex and hydrolyze GM2. To minimize 
these problems, CRISPR-based genome editing was used to pro-
duce a (human) HEK cell line that does not express either the α- or 
β-subunits of HexA, HEKHexABKO (Supplementary Figure S2). We 
also ameliorated some of the potential problems in using a single 
mouse model to confirm the functionality of homodimeric HexM by 
demonstrating that AAV HEXM vectors can reduce GM2 levels in the 
brains of both TSD (Figure 5h) and SD (Figure 6) mice.
Considering that the MUGS Vmax for HexM is approximately twice 
that of HexA (Table  1) and that equal MUGS units of HexA and 
HexM hydrolyze, in a rGM2AP dependent manner, equal amounts 
of NDB-GM2 in vitro (Figure 3c,d), it appears that each of the active 
sites in HexM also have the ability to simultaneously bind and hydro-
lyze a GM2:GM2AP complex. This conclusion is further supported 
by molecular modeling, which indicates that two bound complexes 
could be accommodated in the HexM homodimer.
A promising observation for the potential application of ERT to 
TSD and SD is the reported ability of another lysosomal enzyme, sul-
phamidase, containing an Apolipoprotein B binding domain at its 
C-terminus and expressed in the liver of deficient (MPSIIIA) mice, to 
cross the BBB and correct the enzyme deficiency.40 The potential use 
of a similarly tagged version of HexM for ERT is attractive given the 
high level of expression we have observed in the HEKHexABKO cells 
(~1 mg of Hex M-His6 was purified from 1 l of media collected over 
time from 4× T75 flasks of cells), the observation that secreted HexM 
can be recaptured by TSD cell in a M6P dependent manner, and the 
extreme heat stability of the homodimer (Figure 4b).
The next steps in bringing HexM gene therapy or ERT into the 
clinic is a longer-term trial preferably in a larger animal model 
lacking the biological bypass pathway found in mice, such as the 
TSD sheep,41 prior to human trials. Future studies will also need to 
evaluate whether the incorporation of amino acid residues from the 
β-subunit into the α-subunit to create our hybrid µ-subunit result in 
new epitopes that could elicit an immune response
MATeRIAlS AND MeTHODS
Designing the HexM subunit (μ)
The μ-subunit of HexM was engineered based on the α-subunit structure 
of human HexA. Firstly, the dimerization interface of the HexA α-subunit 
was identified from a PISA analysis (http://www.ebi.ac.uk/pdbe/prot_int/
pistart.html)42 of the HexA crystal structure.3 The identified interface was 
then replaced with residues comprising the more stable homodimeric 
β-subunit:β-subunit interface found in human HexB, which was identified by 
a PISA analysis of the human HexB2 crystal structure. Next, based on a model 
of human HexA bound to a GM2A/GM2 complex,2 two areas of residues near 
the C-terminus of the β-subunit, predicted to be necessary for GM2AP bind-
ing, were used to replace the aligned sequences in the α-subunit (Figures 1 
and 2 and Supplementary Table S1). All structural analyses and modeling 
were carried out using PyMOL (Schrodinger, New York, NY (2010) The PyMOL 
Molecular Graphics System, Version 1.7.4.).
Generation of HEXA and HEXB knockout HEK293T cell line 
(HEKHexABKO) using CRISPR
Guide RNAs specifically targeting exon1 and exon 11 of HexA and exon 1 of 
HexB were chosen from the database of gRNAs targeting the human genome 
described in Mali et  al.43 Oligonucleotides coding for the; (i) HexA gRNA 
targeting exon 1 (CGTCCTTTACGGTGTTTCGTCCTTTCCAC, HumanHexA-
Ex1Rev and TAGCGCTGGTGTTTTAGAGCTAGAAATAGC, HumanHexA-Ex1For); 
(ii) HexA gRNA targeting exon 11 (TCCTATGGCCGGTGTTTCGTCCTTTCCAC, 
HumanHexA-Ex11Rev and TATACGGTTCGTTTTAGAGCTAGAAATAGC, Human-
HexA-Ex11For); and (iii) oligonucleotides coding for the HexB gRNA target-
ing Exon 1 (AGTCAGCAGCGGTGTTTCGTCCTTTCCAC HuHexB-Ex1RevB and 
AGGTGGCGCGTTTTAGAGCTAGAAATAGC, HuHexB-Ex1For) were used to 
replace the guide RNA present in the Church gRNA expression vec-
tor described in Mali et  al. https://www.addgene.org/41824/, Addgene, 
Cambridge, MA) via Round-the-horn site-directed mutagenesis  http://
openwetware.org/wiki/’Round-the-horn_site-directed_mutagenesis using 
Platinum Taq polymerase (Life Technologies, Grand Island, NY) in place of 
the Q5 polymerase in the Q5 Site-directed mutagenesis kit (New England 
Biolabs, Ipswich, MA). Insertion of the appropriate guide RNA sequence 
was verified by DNA sequencing (ACGT, Toronto, Canada). HEK 293T cells 
(100,000–250,000 cells in a six-well plate) were cotransfected overnight with 
HexA and HexB gRNA vectors (125 ng) together with the wild type Cas9 
nuclease expression vector (125 ng) at 1:1:1:1 ratio, using lipofectamine LTX 
(Life Technologies). Following 3 days growth, single transfected cells were 
Figure 6 GM2 levels are significantly reduced in the brains of Sandhoff 
disease mice 8 weeks after neonatal, intravenous injection of a  AAV9.47-
HEXM vector. GM2 levels are expressed as a ratio of the densities of the 
GM2 versus GD1a spots from HPTLC plates (y-axis). Mice injected with 
either vehicle, AAV9.47-HEXM, or AAV9.47-GFP were compared to 
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cloned by limiting cell dilution (ca. 0.5 cells/well) into eight 96-well tissue 
culture plates. After 2 weeks of growth, media were replaced with DMEM 
supplemented with 0.5% HSA and 100 mmol/l NH4Cl to facilitate secretion of 
Hex isoforms into the media, for an overnight incubation. Hex activities were 
evaluated in duplicate aliquots (10 µl) of the media in 384-well plates using 
either MUG (0.4 mmol/l) or MUGS (0.4 mmol/l) as the substrate. Potential 
clones “knocked out” for the HEXA and HEXB genes were identified as those 
wells, which contained cells and had background levels (i.e., medium only) 
of MUG and MUGS activity. Those clones were further expanded and the 
lack of HexA and HexB activity were reconfirmed using MUG and MUGS 
substrates relative to another lysosomal enzyme, β-galactosidase (bGal)44 
(Supplementary Figure S2c). Absence of α- and β-subunits were confirmed 
by western blotting using a previously described rabbit polyclonal Ab 
against Hex A/B44 (Supplementary Figure S2b). HexA exon 11 and HexB exon 
1 and surrounding introns from HEKHexABKO lines were amplified by PCR 
using primers shown in Supplementary Table S2. Resulting amplification 
products were either directly sequenced using the same primers as were 
used for PCR or in the case of HexB exon 1, the product was first cloned into 
PCR2.1 TOPO TA (Life Technologies) prior to sequencing (ACGT, Toronto, 
Canada). Characterization of HexA exon 1 and sequencing of HexA exon 11 
were performed at TCAG (SickKids, Toronto, Canada, we are grateful to Dr. 
Peter Ray and Carol-Ann Ryan for their help). Overlapping sequences in the 
case of HexB exon 1 were deconvolved using PolyPeak Parser (http://yost-
tools.genetics.utah.edu/PolyPeakParser/).
Generation of stable HEKHexABKO line expressing His-tagged HexM
To generate HexM tagged at the C-terminus with poly Histidine (His6), the 
HexM cDNA was amplified with the following: Forward pigBHexHybAttFor2 
(TACAAAAAAGCAGGCTCCaaagccaccatgacctcttctagactgtgg) and Reverse 
primers pigBHxHybHs6AttRev2 (ACAAGAAAGCTGGGTCTCAATGATGATGAT-
GATGATGTCTACCCTCGATagtctgctcaaactcctggttg). The amplified product 
was cloned into gateway entry vector (pENTR201) using the BP reaction fol-
lowed by transfer to the piggybac vector PB-T-RfA45 using the LR reaction, 
according to the manufacturers protocol (Life Technologies). Positive clones 
(PB-T-HexMHis) were verified by DNA sequencing of the HexM cDNA. The 
plasmid PB-T-HexMHis contained the His6 tagged HexM cDNA under the 
control of a tertracycline inducible promotor and flanked with the piggy-
bac 5’ and 3’ terminal repeats, and incorporated the puromycin selectable 
marker. The HEKHexABKO line (ca. 250,000 cells in a six-well tissue culture 
plate) was co-transfected with PB-T-HexMHis, pBASE (coding for the piggy-
bac transposase enabling transposon mediated genomic integration) and 
PB-RB (coding the reverse tetracycline transactivator) at an 8:1:1 weight ratio 
using lipofectamine LTX transfection reagent (Life Technologies). Follow-
ings, 3 days unselected growth, stable tranfectants were selected with Puro-
mycin (2 µg/ml) and Blasticidin S (2 µg/ml), followed by single cell cloning in 
96-well tissue culture plates. After 2 weeks growth, expression was induced 
following addition of 1 µmol/l tetracycline and 100 mmol/l NH4Cl to facilitate 
secretion of HexM. Positive clones were identified by the presence of HexM 
activity in their media monitored with the MUG substrate (1.6 mmol/l).
In the experiments aimed at confirming that secreted HexM could be 
recaptured by deficient cells (adult Tay-Sachs cells), the expression levels 
of HexM from transfected HEKHexABKO cells were high enough that the 
NH4Cl (used to promote the secretion of lysosomal enzymes) could be omit-
ted during the generation of the “conditioned” medium. This eliminated 
the usual dialysis step needed to remove the NH4Cl from the conditioned 
medium before using it to replace the growth media, ± 5 mmol/l M6P, of the 
adult TSD fibroblasts for the 48 hours HexM uptake experiments.
Chemicals, Hex enzyme, and heat stability assays
Sources of the synthetic fluorogenic substrates, MUG and MUGS (Toronto 
Research Chemicals, Toronto, Canada), and their methods of use in the asso-
ciated Hex isozyme assays, and the components that make-up the in cellulo 
and in vitro NBD-GM2 assays have been previously described.22 Kinetic anal-
yses of the Hex isozymes using MUG or MUGS were performed as previously 
described.7 The method of evaluating the heat stability of the purified Hex 
isozymes by differential scanning fluorimetry using NanoOrange has also 
been previously described.29
Cell lines and tissue culture
An adult Tay-Sachs cell line (17662), homozygous for a αG269S missense 
mutation in exon 7 of HEXA,35 was used to demonstrate that secreted HexM 
could be recaptured in a MPR-dependent manner. HEK cells were obtained 
from The Hospital for Sick Children (Toronto, Canada) tissue culture facility. 
All cells were grown in α-minimal essential medium from Wisent (Canada) 
in the presence of 1% antibiotics (penicillin and streptomycin, Wisent, 
Montreal, Canada) and supplemented with 10% fetal bovine serum (FBS) 
(Wisent). The cell lines were grown at 37 °C in a humidified atmosphere with 
5% CO2.
SDS-PAGE and western blots
Western blotting lysates (20 µg WT HEK or 40 µg HEKHexABKO of total pro-
tein) were subjected to SDS-PAGE on a 10% bis:acrylamide gel and trans-
ferred to nitrocellulose (Bio-Rad, Hercules, CA), processed and developed as 
previously.22,35 Silver (protein) staining of the SDS-Page gel was preformed as 
reported by Wray et al.46
Virus and plasmid preparation
Recombinant AAV vectors were generated as described47 using proprietary 
methods developed at the UNC Gene Therapy Center Vector Core facil-
ity (Chapel Hill, NC). The following scAAV9 or 9.47 vectors were produced 
and used for this study: AAV9-GFP, AAV9-HEXA (human), AAV9-HEXM; AAV9-
HEXBMM. The HEXA, HEXM, and HEXB(MM) transgenes were  codon-optimized 
for optimal protein expression in mammalian cells, using DNA2.0 (Menlo 
Park, CA). In order to provide similar transgene expression and allow scAAV 
packaging, all vectors used the same SV40 polyA and a proprietary, short 
synthetic promoter–intron regulatory sequence, provided by J. Keimel and 
M. Kaytor (New Hope Research Foundation, North Oaks, MN).
Experimental TSD and SD mouse models
The Tay-Sachs disease mouse (strain: B6;129S-hexa(-/-)) model developed by 
disruption of the hexa gene48,49 was obtained from The Jackson Laboratory 
and maintained in a 12-hour light–dark cycle with free access to food and 
water. All care and procedures were in accordance with the Guide for the 
Care and Use of Laboratory Animals and received prior approval by the 
University of North Carolina Institutional Animal Care and Usage Committee. 
The different AAV vectors were injected stereotaxically into the brain paren-
chyma of 4-month-old TSD hexa knock-out mice as previously described.50 
The injections were placed between the cortex and striatum, using the fol-
lowing stereotaxic coordinates relative to bregma: rostral/caudal: +0.5 mm 
(toward rostral), left/right: left +3 mm, up/down: −4 mm. Two mice were 
injected with each vector combination. Each injection used a volume of 1 
µl at a rate of 0.1 µl/minute, using a mixture containing 1 × 109 vg of Hex 
vector and 1 × 109 vg of GFP vector. After injection, the mice were allowed to 
recover, and at 4 weeks postinjection, the mice were sacrificed and transcar-
dially perfused with PBS containing 1 U/ml heparin (Abraxis Pharmaceutic 
Products, Shaumburg, IL).
The SD mouse model (strain B6;129S4-Hexbtm1Rlp/J, hexb knock-out) 
was obtained from the Jackson Laboratory (Bar Harbor, ME). All animal 
experiments were carried out under protocols approved by the University 
Animal Care Committee at Queen’s University, Kingston, ON, Canada under 
Canadian Council on Animal Care regulations. The neonatal mice were intra-
venously injected with a AAV9-HEXM vector at day 0–1. They were sacrificed 
at 8 weeks and their mid-brains were collected for determining Hex activity 
as previously described51 and for GM2 analysis (described below).
Immuno-histochemical analysis (TSD mice)
The brains collected from injected TSD mice were fixed in 4% paraformal-
dehyde in PBS for 48 hours and then sectioned at 40 microns using a Leica 
vibrating microtome. One set of sections from the rostral half of the brain 
was immunostained for GFP, and another set was immunostained for GM2 
gangliosides as described.48 Additionally, sections were treated with hydro-
gen peroxide to remove endogenous peroxidase activity prior to blocking. 
The primary antibodies were as follows: rabbit anti-GFP (1:1,000; Millipore, 
Billerica, MA; AB3080) or anti-GM2 (1:1,000; gift from Kyowa Hakko Kirin, 
Tokyo, Japan; KM966). Brain sections were digitized using a Scan-Scope slide 
scanner (Aperio Technologies, Vista, CA). Virtual slides were viewed using 
ImageScope software package (v. 10.0; Aperio Technologies). The Hex activ-
ity was assessed by the clearance of GM2 within the injected region com-
pared to the contralateral brain hemisphere. The area of AAV transduction 
was visualized by staining for GFP.
GM2 ganglioside analysis (SD mice)
Gangliosides were extracted using modification of a method described 
earlier.52 Briefly, murine mid-brain sections were weighed and sonicated in 
0.5 ml methanol at amplitude 15–20% for 3 × 10 second pulses with cooling 
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on ice between pulses (Sonic Dismembrator Model 500, Fisher Scientific, 
Pittsburgh, PA). Samples were centrifuged for 15 minutes at 10,000 RPM at 
4 °C and 0.4 ml of supernatant was removed for enzyme activity studies, the 
remainder was suspended (including pellet) up to a final volume of 1.5 ml 
methanol added to 2.5 ml chloroform. Acidic gangliosides were isolated 
using C18-E columns (Phenomenex, Torrence, CA) and eluted sequentially 
in 2 ml methanol, then in 2 ml 1:1 methanol: Chloroform mixture. The eluate 
was then evaporated under a stream of nitrogen, and the residue is resus-
pended in 1:1 methanol:chloroform and then applied to HPTLC Silica Gel 
60 plate (Fisher Scientific) 10 µl at a time with drying between applications. 
Plates were developed with running buffer (chloroform:methanol:CaCl2 
0.22%—55:45:10). After staining with orcinol (Sigma-Aldrich, St Louis, MO), 
and baking at 105 °C for 10 minutes, plates were immediately scanned for 
Spot Densitometric analysis (Image J software) using a mix of monosialo-
ganglioside standards (Matreya LLC, Pleasant Gap, PA). The ganglioside 
ratios were presented as GM2:GD1a.
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